1) Baxalta wins FDA approval with a treatment for a rare bleeding disease – FierceBiotech, 12/8/2015
Baxalta ($BXLT) picked up FDA approval for a drug that treats von Willebrand disease, a rare inherited bleeding disorder that results from a missing protein.
2) For Epizyme chief executive, the work is personal– Boston Globe, 12/4/2015
Epizyme Inc.’s new chief executive Robert Bazemore understands the disease his company is targeting only too well. When he was introduced to employees this summer, Bazemore surprised them by disclosing that he’s a survivor of non-Hodgkin’s lymphoma, a life-threatening blood cancer that could potentially be treated by the company’s lead drug candidate.
3) Novo Nordisk partners with IBM Watson Health to develop diabetes management tools – BBJ, 12/10/2015
Novo Nordisk plans to use IBM Watson Health to analyze its data on patients with diabetes, announcing today an agreement with the IBM subsidiary.
4) Drug may give those leaving jail a better shot at recovery – Boston Globe, 12/9/2015
But the drug itself may not be the real game-changer, said Dr. Barbara Herbert, president of the Massachusetts chapter of the American Society of Addiction Medicine. More crucial, she said, are efforts by the manufacturer, Waltham drug maker Alkermes, to push prisons to link departing inmates with services on the outside, measures often lacking in the past.
5) FDA approves Alexion drug for ultra-rare disease – Reuters, 12/8/2015
The U.S. Food and Drug Administration on Tuesday approved Alexion Pharmaceutical Inc’s treatment for an ultra-rare and potentially fatal genetic disorder.